Morgan Stanley's Stephen Byrd called the sell-off "significantly overdone, Byrd maintained an Overweight rating with a price target of $104.
Bernstein's Hugh Wynne wrote that the sell-off was "unwarranted," citing a stronger solar installation outlook than when the company initially set 2016 guidance. The analyst expressed confidence in the company's ability to fund its 2016 growth.Stifel Nicolaus, Raymond James and Deustche Bank all upgraded SolarCity to Buy, while lowering their price targets to $65.00, $60.00 and $69.00. Roth Capital also upgraded the company to Buy.
Piper Jaffray Reiterated Rating Overweight $155.00 - $170.00
Business Wire 1/5/16
Consumers File Class Action Against Fitbit, Inc. Alleging That Fitbit Charge HR and Surge Heart Rate Monitors Do Not Accurately Track Users’ Heart Rates
Business Wire Lieff Cabraser Heimann & Bernstein, LLP
SAN FRANCISCO--(BUSINESS WIRE)--
Consumers from California, Colorado, and Wisconsin today filed a nationwide class action lawsuit against Fitbit, Inc. (FIT) alleging that Fitbit’s wrist-based “Charge HR” and “Surge” heart rate monitors do not and cannot consistently record accurate heart rates during the intense physical activity for which Fitbit expressly markets the devices in widespread advertising. The suit contends—and expert testing confirms—that the Heart Rate Monitors consistently mis-record heart rates by a significant margin, particularly during intense exercise. Not only are accurate heart readings important for those engaging in fitness, they can be critical to the health and well-being of people whose medical conditions require them to maintain (or not exceed) a certain heart rate
Shire in advanced talks to buy Baxalta for $48 or more per share, Bloomberg says
The two drug makers could land a deal in the first days of the year. The price being discussed is $48 or more a a share, If a deal succeeds, the enlarged company would generate $20 billion in sales by 2020, with as many as 30 new drugs to launch over five years for diseases ranging from dry eye disease to hemophilia, Shire has said
Analyst Commentary ( SUNE )
Credit Suisse Buy Rating Buy $25.00
Bargain priced, loaded up.l
Fierce Pharma tweeted on Adam f Twitter or go directly to @JohnCFierce
Valeant CEO Sells- Michael J. Pearson, CEO at Valeant Pharmaceuticals (NYSE:VRX) sold 1,297,399 shares at $78.48. The total value of the transaction was approximately $101.83 million.